An overview of pulmonary arterial hypertension: Risks, pathogenesis, clinical manifestations, and management

Journal of Cardiovascular Nursing

Volumn 20, Issue 2, 2005, Pages 108-116

  Cheever, Kerry H ^a  

^a DESALES UNIVERSITY   (United States)

Author keywords

Clinical management; Primary pulmonary hypertension; Pulmonary arterial hypertension; Vasoactive mediators

Indexed keywords

CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; HUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW;

ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, PULMONARY;

EID: 20644446485     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200503000-00005     Document Type: Article

References (35)

1. Rubin LJ, Barst RJ, Kaiser LR, et al. AACP consensus statement: primary pulmonary hypertension. Chest. 1993;104:236-250.
2. Galie N, Manes A, Uguccioni L, et al. Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest. 1998;114:1848-1948.
3. McLaughlin VV, Rich S. Medical and surgical approaches to pulmonary hypertension. Circ Ther. 1997;23:612-616.
4. Cheever KH, Kitzes B, Genthner D. Epoprostenol therapy for primary pulmonary hypertension. Crit Care Nurse. 1999;19(4):20-27.
5. McLaughlin VV. Primary pulmonary hypertension. Hosp Phys Pulm Dis Board Rev Manual. 2002;9:1-11.
6. Rich S. A new classification of pulmonary hypertension. Adv Pulm Hypertens. 2002;1(1):3-6. Available at:.
7. Rich S, ed. Executive summary from the World Symposium on Primary Pulmonary Hypertension; September 6-10, 1998; Evian, France. Available at:. Accessed November 21, 2003.
8. Berkowitz DS, Coyne NG. Understanding primary pulmonary hypertension. Crit Care Nurs Q. 2003;26:28-34.
9. Abenhaim L, Maride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616.
10. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107:216-223.
11. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
12. Nichols WC, Koller DL, Slovis T, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet. 1997;15:277-280.
13. Lloyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis. 1984;129:194-197.
14. Edwards BS, Weir EK, Edwards WD, et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol. 1987;10: 1233-1238.
15. Hadengue A, Behayoun MK, Lebrec D, et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology. 1991;100:520-528.
16. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest. 2000;118:1133-1141.
17. Pellicelli AM, Barbaro G, Palmieri F, et al. Primary pulmonary hypertension in HIV patients: a systematic review. Angiology. 2001;52:31-41.
18. Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest. 1991;100: 1268-1271.
19. McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after therapy with fenfluramine. BMJ. 1986;292:239-240.
20. Gomez-Sanchez MA, Mestre de Juan MJ, Gomez-Pajuelo C, Lopez JI, Diaz de Atauri MJ, Martinez-Tello FJ. Pulmonary hypertension due to toxic oil syndrome: a clinicopathologic study. Chest. 1989;95:325-331.
21. Frazier SK. Diagnosing and treating primary pulmonary hypertension. Nurse Pract. 1999;24:18-43.
22. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
23. Mikhail G, Chester AH, Gibbs JS, Borland JA, Banner NR, Yacoub MH. Role of vasoactive mediators in primary and secondary pulmonary hypertension. Am J Cardiol. 1998;82:254-255.
24. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995;75:3A-10A.
25. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev. 2000;80:1337-1372.
26. Dinh-Xuan AT. Endothelial modulation of pulmonary vascular tone. Eur Respir J. 1992;5:757-762.
27. Hughes JD, Rubin LJ. Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature. Medicine. 1986;65:56-72.
28. Rhodes J, Barst RJ, Garofano RP, et al. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol. 1991;18: 1738-1744.
29. Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation? Am J Cardiol. 1995; 75:63A-66A.
30. Cremona G, Higenbottam T. Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol. 1995;75:67A-71A.
31. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338: 273-277.
32. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation. 1997;96:2782-2784.
33. Olschewski H, Ghofrani HA, Walmarath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med. 1999;160:600-607.
34. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist Bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001;358:1119-1123.
35. Conte JV, Borja MJ, Patel CB, Yang SC, Jhaveri RM, Orens JB. Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg. 2001;72:1673-1679.